CME: Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl - PACE-CME

Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl

3 episodes

1.00 program credits

36m

Improving the management of patients with atherosclerotic cardiovascular disease

Details

Episodes

Documents

Presenters

Comments

Overview
Even after reaching LDL-c targets, residual CV risk can remain high. Icosapent ethyl has been indicated as an adjunct to maximally tolerated statin therapy in adults with elevated triglyceride levels and CVD or DM with at least two additional CV risk factors to reduce risk of CV events. In this series, three experts discuss triglyceride-related CV risk, review studies with omega-3 fatty acids and talk about how to integrate treatment with icosapent ethyl in clinical practice.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of 3 presentations on triglyceride-related CV risk and icosapent ethyl.
Challenges in ASCVD reduction and TG-related risk - Erik Stroes, MD, PhD - Amsterdam, The Netherlands
- In this video, Erik Stroes explains the relationship between triglyceride-rich lipoproteins and atherogenic risk.
Perspectives on the results of recent clinical outcomes trials with EPA prevention - Gabriel Steg, MD - Paris, France
- Gabriel Steg gives a comprehensive overview of trials that investigated the effect of EPA on CV outcomes.
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance - Pam Taub, MD - La Jolla, CA, USA
- Pam Taub talks about how to integrate icosapent ethyl in the day-to-day clinical practice to reduce CV risk.
Instructions
- Watch the three lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@pace-cme.org.
Learning Objectives
- Explain the association between triglyceride-rich particles and atherosclerotic risk
- Select an explanation for the benefit of icosapent ethyl
- Define practical considerations in treating patients with elevated triglycerides
Target Audience
This educational activity is designed for all healthcare professionals with an interest in management of patients at risk of ASCVD.
Accreditation and Credit Designation Statements
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from Amarin.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date: 05/12/2023
Expiration Date: 05/12/2025

Documents

Slides Erik Stroes.pdf

Slides Gabriel Steg.pdf

Slides Pam Taub.pdf

Presenters

Erik Stroes, MD, PhD

Erik Stroes, MD, PhD

P. Gabriel Steg, MD

P. Gabriel Steg, MD

Pam R. Taub, MD, FACC, FASPC

Pam R. Taub, MD, FACC, FASPC

Facebook Comments